Metronomic Capecitabine plus Docetaxel as first line treatment for metastatic breast cancer patients: a phase II trial - ND

ISTITUTO EUROPEO DI ONCOLOGIA0 个研究点开始时间: 2009年4月1日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients (female) with documented advanced/metastatic breast cancer without HER-2/neu over expression ( IHC 3+ or FISH positive)
•Patients may not have received a previous chemotherapy regimen for metastatic breast cancer
•Patients may have received previous hormonal treatment for endocrine responsive metastatic disease.
•Patients may have received chemotherapy with taxanes as adjuvant treatment provided that metastatic disease occurred at least 6 months after the completion of adjuvant chemotherapy.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients who have received:
•-1 or more regimens of chemotherapy for metastatic disease;
•-taxanes in the adjuvant setting < 6 months from study entry
•Patients with HER2 overexpressing metastatic breast cancer
•Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
•Presence of known clinical brain or meningeal involvement.
•Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient;
•Concomitant treatment with other anticancer (chemotherapy or endocrine therapy) drugs.
•Concomitant treatment with any other experimental drug.

发起方